PLSE

Pulse Biosciences, Inc. develops and commercializes its proprietary nPulse™ technology, which utilizes Nanosecond Pulsed Field Ablation (nsPFA) energy for medical applications. The company focuses on soft tissue ablation, specifically targeting benign thyroid tumors and cardiac conditions such as atrial fibrillation. Its products are designed to provide minimally invasive treatment options, enhancing patient care in the fields of electrophysiology and thyroid health. Pulse Biosciences operates primarily in the healthcare sector, serving hospitals and medical professionals globally.